HitGen focuses on the discovery and development of innovative therapeutics targeting diseases with limited treatment options. According to a Reuters report dated 20 November 2025, the company has secured fresh financing to advance its pipeline of novel drug candidates. The capital will be used to further research and development efforts, with an emphasis on addressing medical areas that currently lack effective therapies. Although specific product names or platforms were not detailed, the funding underscores investor confidence in HitGen’s scientific approach. The new infusion strengthens the company’s financial position and supports continued progression toward clinical milestones. No operational metrics or revenue figures were disclosed in the article. The report did not specify the company’s historical performance or additional strategic initiatives beyond advancing its therapeutic portfolio.

Total raised

$39M

Funding rounds

1

Latest round

Series B

Latest activity

May 2018